Project Grant R01HL175722

Award Date 9/17/24
Completion Date 6/30/28
Dollars Obligated $574K
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This Project Grant award of $629,319 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Emory University supports research to overcome defects in the CFTR gene that cause cystic fibrosis. The research aims to investigate how modulating ribosomal proteins can rescue the synthesis and assembly of CFTR variants with premature termination codons, which are associated with more severe disease. The project will explore the mechanisms by which ribosomal...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 5-year, $756,875 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Cincinnati to investigate the molecular mechanisms by which neutrophil extracellular traps (NETs) contribute to airway damage and infection in mucoobstructive lung diseases like cystic fibrosis. The research aims to understand how NETs mediate inflammation and infection by targeting the epithelial junction protein E-cadherin, and...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $683,564 to The Trustees of the University of Pennsylvania to conduct research on alveolar epithelial stress signaling in lung fibrosis. The key objectives are to determine how aberrant transitional epithelial cells contribute to fibrosis, and to define how the PERK-ISR signaling pathway impacts epithelial differentiation and promotes fibrosis. The research will...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $730,494 to Emory University from February 1, 2025 to December 31, 2029 to investigate the mechanisms linking cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction to impaired barrier function, insulin receptor function, and glucose transport in the cystic fibrosis (CF) lung. The grant also supports a sub-award to Vanderbilt University...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $636,843 to The Regents of the University of California, San Francisco to conduct research aimed at characterizing a targetable stromal factor that alters immune cell accumulation in the lung and defines the downstream effects of these immune cells on airway epithelial cells. The research project, titled "Targeting the Stromal Niche for...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $684,814 to The Regents of the University of California, San Francisco to conduct research on the suppression of alveolar stem cells by tissue-resident lymphocytes in emphysema. The primary objectives are to investigate how lung stromal factors modify the inflammatory response to viral infections and tobacco smoke, and how this leads to the suppression of alveolar...
This $651,019 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is funding research to elucidate the mechanisms behind dysfunctional epithelial repair processes that contribute to the development of pulmonary fibrosis. The research aims to identify factors driving aberrant epithelial cell states, determine the role of HIF signaling in preventing functional alveolar repair, and investigate niche-specific mechanisms regulating...
This Project Grant award of $915,924 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate how disruptions to early-life microbial colonization of the lungs, such as through antibiotic use, can lead to chronic respiratory diseases by remodeling the developmental pathways of lung-resident immune cells and epithelial cells. The research aims to define the specific microbial taxa essential for establishing lung homeostasis...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research) provides $480,990 to the University of Illinois to conduct research on the role of aerocytes, a recently identified capillary endothelial cell population, in regulating alveolar regeneration following lung injury. The research aims to establish the central role of aerocytes and the signaling molecule R-spondin3 in guiding regenerative alveolar remodeling, with the...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $155,196 to The University of Texas Southwestern Medical Center to conduct research on how biophysical force affects type 1 alveolar epithelial cell-mediated regulation of the pulmonary matrisome and lung development. The 5-year research project aims to 1) identify how elevated mechanical stress impacts type 1 alveolar epithelial cell regulation of the pulmonary...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $574,000 to The University of Texas Southwestern Medical Center to investigate the effects of estrogen on neutrophil function and airway inflammation in cystic fibrosis (CF) and non-CF bronchiectasis. The research aims to understand how estrogen impacts neutrophil dysregulation and inflammation, which may contribute to sex differences in lung disease and outcomes in these patient populations. The expected outcome is a comprehensive understanding of the estrogen-mediated pathways involved, which could reveal therapeutic targets such as the potential use of nebulized estrogen receptor antagonists. The award period runs from September 2024 through June 2028.

Generated 7/15/25, 8:02 AM